 Connection
Nishank Jain to Purinergic P2Y Receptor Antagonists
This is a "connection" page, showing publications Nishank Jain has written about Purinergic P2Y Receptor Antagonists.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
3.376 |
|
|
|
-
Jain N, Martin BC, Dai J, Phadnis MA, Al-Hindi L, Shireman TI, Hedayati SS, Rasu RS, Mehta JL. Age Modifies Intracranial and Gastrointestinal Bleeding Risk from P2Y12 Inhibitors in Patients Receiving Dialysis. Kidney360. 2022 08 25; 3(8):1374-1383.
Score: 0.805
-
Jain N, Phadnis MA, Martin BC, Mehta JL. Potent Antiplatelet Therapy May Reduce Death from Sepsis in Patients on Chronic Dialysis. Am J Cardiol. 2022 01 01; 162:209-211.
Score: 0.775
-
Jain N, Hunt SL, Cui H, Phadnis MA, Mahnken JD, Shireman TI, Dai J, Mehta JL, Rasu RS. Trends for and Clinical Factors Associated with Choice of Oral P2Y12 Inhibitors for Patients on Chronic Dialysis. Cardiovasc Drugs Ther. 2019 10; 33(5):511-521.
Score: 0.671
-
Singh M, Raghavan D, Williams JS, Martin BC, Hudson TJ, Owen RR, Jain N. Prevalence of Chronic Kidney Disease, Thrombotic Cardiovascular Events, and Use of Oral P2Y12 Inhibitors among Veterans. Am J Nephrol. 2018; 47(2):67-71.
Score: 0.598
-
Jain N, Reilly RF. Oral P2Y12 Receptor Inhibitors in Hemodialysis Patients Undergoing Percutaneous Coronary Interventions: Current?Knowledge and Future Directions. Semin Dial. 2016 09; 29(5):374-81.
Score: 0.527
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|